• The predictors of clinical response to DPP-4 inhibitors were age, ethnicity, and HbA1c at baseline.
• Older patients with DPP-4 inhibitor associated with higher degree of DPP-4 inhibition.
• The association between age and HbA1c reduction was dependent on higher degree of DPP-4 inhibition.

• Insulin pump treatment did not outclass injection therapy with regard to hemoglobin A1c, cardiovascular risk factor control or diabetes-associated complications in this real-world collective.
• Hypoglycemia and use of sensor-augmented therapy improved within the pump treatment group.
• Future research questions should address hybrid-closed and closed loop systems and incorporate newer target parameters.
• Rapid advancements in diabetic technologies need to be evaluated before implementation in daily diabetes management.